Skip to content

Effects of the Vitamin C Derivative K3A on Symptoms of Atopic Dermatitis

Effects of the Vitamin C Derivative K3A on Symptoms of Atopic Dermatitis: Open-label study - Effects of the Vitamin C Derivative K3A on Symptoms of Atopic Dermatitis: Open-label study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000061611
Enrollment
4
Registered
2026-05-18
Start date
2026-05-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Apply test products for 7 days

Sponsors

Miura Clinic, Medical Corporation Kanonkai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Men and women aged 20 to 59 and over with symptoms of atopic dermatitis on the face or body (2) Subjects with an EASI score of 1.1 or higher (3) Subjects who have not undergone treatment for atopic dermatitis for a certain period and have not used alternative therapies (4) Subjects who have received a thorough explanation of the purpose and content of the trial, has the capacity to consent, understands it well, voluntarily agrees to participate, and has given written consent to participate in the trial

Exclusion criteria

Exclusion criteria: (1) Subjects who used topical treatments for atopic dermatitis within 4 weeks prior to the screening test date (2) Subjects who received systemic administration (oral or intravenous) of steroids, immunosuppressants, or JAK inhibitors within 8 weeks prior to the screening test date Subjects who have undergone gastrointestinal surgery (3) Subjects who regularly take anti-inflammatory oral medications or anti-allergy drugs (4) Subjects who have previously received treatment with biological agents or phototherapy (5) Subjects with a history of mental illness, diabetes, liver disease, kidney disease, gastrointestinal disease, heart disease, respiratory disease, peripheral vascular disorder, or other serious illnesses (6) Subjects who have undergone gastrointestinal surgery (7) Subjects with an ongoing medical condition (8) Subjects of allergies to cosmetics or food (Including those who have experienced skin reactions such as rashes from cosmetics within the past year) (9) Subjects who have significant abnormalities on the skin of the test site, or who have severe atopic dermatitis symptoms (10) Women who wish to become pregnant during participation in this trial, women who are pregnant (including the possibility of being pregnant), or women who are breastfeeding (11) Subjects whose skin condition changes drastically due to menstrual irregularities or menstruation (12) Individuals who engage in intense sports and subjects who are on a diet (13) Subjects with extremely irregular eating habits (14) Subjects working night shifts and rotating day-night shifts (15) and beyond are described in Other related information.

Design outcomes

Primary

MeasureTime frame
Medical interview Visual examination Clinical findings (EASI score, IGA score, assessment of skin rash severity) Photographs

Countries

Japan

Contacts

Public ContactMakoto Terashima

Oneness Support Co., Ltd. Clinical Trial Division

mterashima@oneness-sup.co.jp06-4801-8917

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026